

#### Disclosures

I have received funding from the following companies for providing educational sessions, attending advisory and editorial boards and received travel grants to attend conferences:

- Teva
- Allergan
- Continuum journal
- Novartis

### CASE 1

35 year old female

Presents to neurologist with headache

Patient has googled her disorder

Neurologist disagrees with Google

# Symptoms

2 year history

Headache

Photophobia

Phonophobia

Neurologist- Migraine

#### Migraine- 12% general population<sup>1</sup>

Migraine is more prevalent than diabetes, epilepsy and asthma combined<sup>2</sup>

#### Costly


NZ- 3431 discharges Migraine (others- 592)<sup>3</sup>

Majority 20-49 age group


Maori - 497 migraine discharges

- <sup>1</sup>Lipton *et al.*, Headache. 2001
- <sup>2</sup>Natoli JL *et al.*, Cephalalgia. 2010
- <sup>3</sup>Ministry of Health NZ data 2016/17

# Primary neuronal dysfunction



CGRP- Calcitonin gene related peptide CSD- Cortical spreading depression Genetic- FHM1,2,3, TRESK Hormonal- Serotonin, Oestrogen



#### Burden

Second most disabling<sup>1</sup>


Substantial negative impact on patients' lives and their familial, social, and professional environment<sup>2</sup>

Cost- US 17 Billion \$ per year<sup>3</sup>

<sup>&</sup>lt;sup>1</sup>Global burden of disease Lancet 2017

<sup>&</sup>lt;sup>2</sup>Patient perceptions of the impact and burden of migraine: an international survey of 12,545 patients across 16 countries- MTIS 2020

<sup>&</sup>lt;sup>3</sup>Goldberg. The cost of migraine and its treatment. Am J Manag Care. 2005



J Headache Pain (2012)

## Presenting symptoms

Number of headache days out of 30 per month

Crystal clear days<sup>1</sup>

Site/Character/Duration

Circadian/Circannual periodicity<sup>2</sup>


Thunderclap?

Valsalva

Postural variation

<sup>&</sup>lt;sup>1</sup>Khalil *et al.,* Prospective analysis of the use of Onabotulinumtoxin A (BOTOX) in the treatment of chronic migraine J Headache Pain. 2014 <sup>2</sup>May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet. 2005

### Associated features



Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias

206

Episodic migraine - 4%

Chronic Migraine - 13%


Chronic Cluster headache - 48%

Episodic cluster headache - 80%

Hemicrania Continua- 56%, SUNCT- 56%


Lateralization > in TACs than migraine ( $\chi^2 = 84.9$ , P < 0.0001)

# Migraine phases




### FUNCTIONAL IMAGING


• Premonitory (Prodrome)



• Postdrome




#### **OTHERS**



CAS (Cranial autonomic symptoms - ptosis/red eyes/watering/rhinorrhea)
Drug History- ? Max dose of preventives/ ? Side-effects
Medication overuse— Paracetamol/NSAIDS 15/30, Opiates- 10/30, Triptans 10/30

# **TRIGGERS**



#### Examination

Changes to behavior/personality

Confusion

Papilledema

Ophthalmoplegia

Focal neurological deficits

#### RED FLAGS- SNOOP

Systemic symptoms including fever

Neoplasm history/Neurological deficit

Onset sudden, Older age (onset after age 50 years)

Pattern change, Precipitated by sneezing, coughing, or exercise

Progressive headache, Pregnancy or puerperium

Painful eye with autonomic features

Pathology of the immune system such as HIV

Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Do et al., Neurology. 2019

### CASE 1

35 year old female

Presents to neurologist with headache

Patient has googled her disorder

Neurologist disagrees with Google

# Symptoms

2 year history

Headache

Photophobia

Phonophobia

Neurologist- Migraine

# Symptoms

- 2 year history
- Headache- Right sided retro-orbital

Sharp/piercing pain

Lasts around 1 hour

Usually at 2 am

With unilateral cranial autonomic symptoms

Lasts 6-8 weeks

Completely symptom free in between.

- Photophobia- Right sided
- Phonophobia- Right sided

#### MIGRAINE

>5 attacks

4-72 hours

2 of (unilateral, pulsating, moderate to severe, aggravation with activity)

Nausea/Vomiting

Photophobia/Phonophobia

#### Cluster Headache

'Suicide headaches'

>5 attacks

Very severe unilateral orbital/supraorbital/temporal pain

15-180 mins

Ipsilateral cranial autonomic symptoms

Restlessness or agitation during attacks

# \*Migraine Management – Acute (Non-triptan)

| Drug        | Dose        | Max dose 24 hours |  |
|-------------|-------------|-------------------|--|
| Paracetamol | 1000 mg     | 4000 mg           |  |
| Ibuprofen   | 400-600mg   | 2400 mg           |  |
| Aspirin     | 600-1000 mg | 4000 mg           |  |
| Naproxen    | 250-500 mg  | 1000 mg           |  |

<sup>\*</sup> Based on RCT data / At least 2 international treatment guidelines

# \*Migraine Management – Acute (Triptans)

| Drug                     | Dose      | Max dose 24 hours |
|--------------------------|-----------|-------------------|
| Sumatriptan oral         | 50-100 mg | 300 mg<br>12 mg   |
| Sumatriptan injection    | 6mg       | 12 mg             |
| Rizatriptan**            | 10 mg     | 20 mg             |
| Zolmitriptan nasal spray | 5 mg      | 10 mg             |

<sup>\*</sup> Based on RCT data / At least 2 international treatment guidelines \*\*Drug interaction Rizatriptan/Propranolol- use 5 mg instead

### Preventives- Episodic and Chronic Migraine

| Drug          | Dose             | Titration | Trial Study dose |
|---------------|------------------|-----------|------------------|
| Amitriptyline | 10-25 mg         | 10-25 mg  | 25-150 mg        |
| Propranolol   | 10 mg BD         | 10-20 mg  | 120-240 mg       |
| Topiramate    | 25 mg            | 25 mg     | 25-200 mg        |
| Candesartan   | 2 mg             | 2 mg      | 8-16 mg          |
| Botox*        | 155 u every 3/12 |           |                  |

Based on RCT data / At least 2 international treatment guidelines Sodium valproate/Pizotifen- weight gain \*Chronic migraine

## CGRP Monoclonal Antibodies

| Commercial | Eptinezumab                                       | Erenumab           | Galcanezumab                                | Fremenezumab                          |
|------------|---|--------------------|---|---------------------------------------|
| Name       | ALD403  | AMG334             | LY2951745                                   | TEV-48125                             |
| Туре       | Humanised   | Human              | Humanised                                   | Humanised                             |
|            | Yeast   | Murine             | Murine                                      | Murine                                |
| Trials     | Promise 1 (E)<br>Promise 2 (C)<br>Prevail (OL LT) | Arise & Strive (E) | Evolve 1 & 2 (E)<br>Regain (C)<br>Conquer © | Halo (E)<br>Halo (C)<br>Focus (OL LT) |
| Against    | CGRP  | Receptor           | CGRP  | CGRP                                  |
| Route/Dose | IV every  | SC every           | SC every                                    | SC every                              |
|            | 12 weeks  | 4 weeks            | 4 weeks                                     | 4 weeks                               |
| Studies    | Migraine  | Migraine           | Migraine<br>Cluster                         | Migraine<br>Cluster                   |

#### Cluster headache – Acute Treatment

High Flow oxygen 15L/min- nonrebreathing facial mask

Sumatriptan injection

Avoid oral triptans

#### Cluster Headache - Preventives

| Drug                          | Dose                             | Titration          | Max dose      |
|-------------------------------|----------------------------------|--------------------|---------------|
| Verapamil                     | 80 mg TDS                        | 80 mg              | 960 mg        |
| Topiramate                    | 25 mg OD                         | 25 mg              | 200 mg        |
| Prednisolone                  | 60mg OD- 5 days                  | Reduce by 10mg/day | 10-day course |
| Greater occipital nerve block | Methylpred-80mg<br>Lignocaine 2% |                    |               |


Based on RCT data / At least 2 international treatment guidelines
Sodium valproate/Pizotifen- Limited evidence
Lithium – narrow therapeutic window
Galcanezumab – CGRP monoclonal antibody

#### KEY POINTS FROM THIS CASE

Cluster headache is still commonly missed<sup>1</sup>

Unilateral photo/phonophobia can be helpful

Artificial intelligence is getting smarter



#### CASE 2

68 yr old female

On holiday in Spain


Sunbathing at onset of headache

Abrupt onset of headache

Left occipital region, throbbing, photophobia, lightheaded

ED in Spain – diagnosed migraine and discharged with analgesia

Represented to ED in UK



# Subarachnoid Haemorrhage

Thunderclap headache (sudden explosive, pain peaks in 1 min or less)

'Worst ever'

CT head (98% <6 hours)

CSF Xanthochromia – After 12 hours

1 in 20 missed in Emergency department

Common reason neurologists sued!

# Thunderclap Headache

Subarachnoid haemorrhage

Cervical arterial dissection

Cerebral venous sinus thrombosis

Pituitary apoplexy

Spontaneous intracranial hypotension

Reversible cerebral vasoconstriction syndrome (RCVS)

Stroke

#### CASE 3

57 yr female

3-month history throbbing headaches/photophobia/phonophobia (Migraine)

5 days before presentation- weakness right upper limb - 10 minutes followed by frontal headache - 5 minutes

Admission day- weakness left upper limb – 10 minutes

#### MEDICAL TEAM

Afebrile

BP 134/90

Completely normal neurological examination

CT head reported as normal

Medical Team-? Transient Ischaemic attack? Migraine

Full blood count, Urea and electrolytes, CRP, Glucose

**Neurology Opinion** 

## Neurology Review

All symptoms settled

Patient keen to go home

Left carotid bruit

Harsh systolic cardiac murmur

ESR, vasculitis screen


Carotid Doppler


Echocardiogram

MRI Brain and MR Angiogram requested


Started antiplatelets (? TIA)

Admit under Neurology













## TAKAYASU'S ARTERITIS

1908 - Dr Mikito Takayasu


Large vessel vasculitis


Multisystem (joints, brain, heart, lung, gastro)

Neurology - headaches, strokes

## Differentiating between TIA/stroke and migraine with aura

| TIA/Stroke  | Migraine with Aura  |
|---|---|
| Negative symptoms   | Positive, then negative symptoms  |
| All symptoms at onset   | Gradual spread over minutes   |
| Symptoms clear together in TIA  | Symptoms may clear in one modality before onset of symptoms in another modality |
| Can affect more than one modality simultaneously  | Spreads from one modality to another  |
| Duration up to 30 min most common in TIA, but can last hrs; enduring deficits in stroke | 20-30 min aura is most common, usually followed by headache                     |
| Usually >40 yrs old   | Often begins in teens or twenties   |
| Stroke risk factors present   | Often a personal/family history of migraine                                     |





Stroke CSD

## Potential new neuropeptide targets

**CGRP** 

PACAP-38

PACAP -27

VIP

AMY<sub>1</sub> receptor

5'-triphosphate sensitive potassium (KATP) channels

Voltage-activated potassium (BK) channel

Dickenson *et al.*, data presented at MTIS 2020 PACAP- Pituitary adenylate cyclase-activating peptide VIP- Vasoactive intestinal peptide AMY1- Amylin

## TAKE HOME MESSAGES

Headache is a common medical complaint

Costly and major cause of disability

Early diagnosis and management is key

Novel treatments on the horizon

https://aucklandregion.healthpathways.org.nz